LUTATHERA Injection General Use Result Survey (Somatostatin Receptor-positive Neuroendocrine Tumor, CAAA601A11401)
LUTATHERA Injection General Use Result Survey (Somatostatin Receptor-positive Neuroendocrine Tumor, CAAA601A11401)
This study was a multicenter observational study with a central registration system and all-case surveillance system without a control group.
From the date of the first dose of this drug until 40 weeks after the date of the last dose (64 weeks if 4 doses are administered 8 weeks apart).
For patients who discontinue treatment with this drug during the observation period, necessary variables were examined until 40 weeks after the last dose of this drug during the observation period and recorded in the case report forms (CRF).
Inclusion Criteria:
All patients treated with this drug for the following indications during a certain post-marketing period
Exclusion Criteria:
Kita-gun, Kagawa-ken 7610793, Japan
Sunto Gun, Shizuoka 411 8777, Japan
Bunkyo-ku, Tokyo 1138519, Japan
Chuo Ku, Tokyo 104 0045, Japan
Koto Ku, Tokyo 135 8550, Japan